Open Access

Pro/con clinical debate: Are steroids useful in the management of patients with septic shock?

  • Frank V Ritacca1,
  • Carmine Simone2, 3,
  • Randy Wax4, 5,
  • Katherine G Craig6 and
  • Keith R Walley7
Critical Care20026:113

https://doi.org/10.1186/cc1467

Published: 6 February 2002

Abstract

Decision-making in the intensive care unit is often very difficult. Although we are encouraged to make evidence-based decisions, this may be difficult for a number of reasons. To begin with, evidence may not exist to answer the clinical question. Second, when there is evidence it may not be applicable to the patient in question or the clinician may be reluctant to apply it to the patient based on a number of secondary issues such as costs, premorbid condition or possible complications. Finally, emotions are often highly charged when caring for patients that have a significant chance of death, and care-givers as well as families are frequently prepared to take chances on a therapy whose benefit is not entirely clear. Steroid use in septic shock is an example of a therapy that makes some sense but has conflicting support in the literature. In this issue of Critical Care Forum, the two sides of this often heated debate are brought to the forefront in an interesting format.

Keywords

glucocorticoidssepsisshock

The scenario

A 60-year-old man has been in your intensive care unit with septic shock for 5 days and he has required a norepinephrine infusion for the entire time. He had multisystem organ failure but most of the organs have improved. He has good urine output and does not have any evidence of heart failure. There is no active bleeding and currently no signs of new or ongoing infection. You wonder whether steroids might help facilitate his recovery.

Pro: Steroids are useful in the management of septic shock

Frank V Ritacca, Carmine Simone and Randy Wax

Despite advances in providing care for patients with septic shock, mortality rates remain unacceptably high. Exogenous corticosteroids have potent anti-inflammatory effects and their use for modulation of the host response in septic shock has been debated for decades. Two meta-analyses have suggested that high-dose steroids are not beneficial in patients with septic shock [1,2]. These results should not be generalized to treatment with low-dose corticosteroids. We believe there are recent data showing that low-dose corticosteroids hasten discontinuation of vasopressors in refractory septic shock, and may improve outcome.

Demonstration of an intact hypothalamic-pituitary-adrenal axis response has been associated with reduced mortality in septic shock [3]. Corticosteroids can regulate the synthesis and function of catecholamines and their receptors, which in turn control vascular tone and organ perfusion [4]. Proinflammatory cytokines released in sepsis alter steroid responsiveness, leading to the deleterious effects of catecholamine dysfunction and refractory hypotension [5]. Downregulation of catecholamine receptors occurs with prolonged use of exogenous catecholamines and this may be reversed with administration of low-dose steroids [6]. Restoring endogenous regulation of vasomotor tone would be desirable to preserve regional regulation of perfusion.

Three recent clinical trials have provided encouraging results for the use of corticosteroids in septic shock (Table 1). Patients were treated with corticosteroids at lower doses and for a longer interval than in previous trials. Bollaert et al. showed that patients receiving low-dose steroids had a significantly higher rate of shock reversal (stable blood pressure without fluid boluses or vasopressors) [7]. The treatment effect was present irrespective of hypothalamic-pituitary-adrenal axis function as measured by an adrenocorticotrophic hormone (ACTH) stimulation test.
Table 1

Summary of prospective studies suggesting benefit for use of corticosteroids in patients with septic shock

Study

Design

Therapy

Outcome

Bollaert et al. [7]

Prospective, randomized, double-blind, placebo-controlled trial

100 mg hydrocortisone intravenously every 8 h for 5 days

Shock reversal at 7 days; treatment, 68% (15/22); placebo, 21% (4/19). P = 0.007

Briegel et al. [8]

Prospective, randomized, double-blind, placebo-controlled trial

100 mg hydrocortisone intravenous loading dose plus infusion at 0.18 mg/kg/h until shock reversal, then wean infusion

Median time to cessation of vasopressor support; treatment (n = 20), 2 days versus placebo (n = 20), 7 days. P = 0.005

Annane [9]

Prospective, randomized, double-blind, placebo-controlled trial

50 mg hydrocortisone intravenously every 5 h + 50 μg fludrocortisone perorally once daily for 7 days

28-day survival by Cox model, 28.8% relative risk reduction for treatment (n = 150) versus placebo (n = 149). Relative risk, 0.712; 95% confidence interval, 0.525–0.965

Briegel et al. similarly found that low-dose corticosteroids could hasten independence from vasopressor support [8]. There were no trends suggesting treatment-related adverse events in either trial. Although no mortality benefits were found, increased rates of shock reversal may imply decreased resource use (e.g. shorter length of stay in the intensive care unit) and complications (e.g. catheter-related infections).

Data published in abstract form from a multicenter trial testing low-dose corticosteroid and mineralocorticoid support led to a relative risk reduction of almost 30% in patients with septic shock [9]. The survival benefit of combination therapy was significant only in patients with blunted response to ACTH stimulation. However, this may be due to a smaller number of patients in the normal response group.

Finally, one retrospective study suggests that low-dose corticosteroids may reduce post-traumatic stress disorder and improve health-related quality of life in survivors of septic shock [10].

Although exciting developments in targeted drug therapy for sepsis have occurred recently, supportive care remains key to maximizing survival in patients. We view appropriate supplementation of corticosteroids as part of the regimen of supportive care. Even if subsequent studies do not confirm a mortality reduction, 'fewer days of vasopressor dependence' may itself be an important outcome. Given that the patient described for this debate appears to have been adequately treated for infection, repair of sepsis-induced dysregulation of vasomotor tone using low-dose corticosteroids is reasonable and appropriate.

Con: Steroids are not useful in the management of septic shock

Katherine G Craig and Keith R Walley

The debate surrounding the use of corticosteroids in septic patients has continued for over 30 years. Two meta-analyses in the mid-1990s seemed to put an end to the controversy. The conclusions drawn from these works were that corticosteroids provided no benefit to patients with septic shock [2] and that corticosteroids may actually cause harm, as evidenced by a slight increase in overall mortality [1].

The debate has recently been re-opened by several small, prospective, randomized, placebo-controlled trials. A study by Bollaert et al., in which septic patients requiring catecholamines were randomized to receive hydrocortisone (100 mg intravenously three times a day for 5 days) or placebo, found a significant reduction in the time it took to reverse shock, and a trend towards improved survival [7]. While the results of this trial were impressive, care must be taken not to overinterpret the results; it was a small clinical trial with only about 20 patients in each arm, and there was a relatively high mortality rate in the placebo arm (63%) for patients with septic shock [11].

In a similar small trial by Briegel et al., septic shock patients were randomized to receive either a placebo or hydrocortisone (100 mg intravenous bolus), followed by continuous infusion until septic shock resolved [8]. The length of time for which vasopressor support was required was significantly reduced, and measures such as mean arterial pressure and systemic vascular resistance index were increased in patients treated with steroids. In addition, there were trends toward earlier reversal of organ dysfunction. There was not, however, a mortality difference between the two groups [8].

It may be germane to recognize that all benefit of immunomodulatory therapy in adequately powered, randomized, controlled trials is confined to the most severely ill [12,13,14,15]. This does not fit with the patient described in the aforementioned scenario.

Clinical case

In view of conflicting older, yet strong, evidence (that high-dose steroids are not beneficial) and newer, yet preliminary, studies (that suggest low-dose steroids are beneficial), the question becomes one of whether steroid-induced reversal of vasopressor support confers any outcome benefits. Unfortunately, no definitive work has been published.

The patient described in the present scenario is improving in all aspects of organ failure, but remains catecholamine dependent. A thorough examination and review of his management needs to be conducted to ensure no reversible cause of hypotension can be determined. A corticotropin stimulation test should be performed and absolute adrenal insufficiency should be treated.

There is ongoing debate in the literature as to the usefulness of this corticotropin stimulation test in so-called 'relative adrenal insufficient' patients, although it may be of prognostic significance [16]. A recent study by Schroeder et al. found low basal plasma cortisol levels and diminished responses to corticotropin-releasing hormone in patients that died of septic shock as compared with those who survived [17]. Annane et al., however, found an elevated basal cortisol level (≥ 34 μg/dl) and a poor response to corticotropin (e.g. ≤ 9 μg/dl elevation at 30 or 60 min) to be a predictor of the poorest survival in patients with sepsis [3].

At this point in time there is not sufficient evidence to guide clinical practice. We therefore do not advocate use of steroids in this clinically improving patient without another indication. We must be cautious in our enthusiasm to try new therapies as history provides many examples of promising small clinical trials that have not held up to the test of time and larger, multicentered trials.

Pro's response to Con's arguments

Frank V Ritacca, Carmine Simone and Randy Wax

Applying data from trials using high-dose steroids is inappropriate and leads to therapeutic nihilism. Life-saving therapy, such as low-dose beta-blockers in severe cardiomyopathy, met similar resistance because of poor experiences with identical drugs given in higher doses [18].

Levels of cortisol and responsiveness to ACTH stimulation in patients with sepsis vary considerably [19,20,21]. A normal corticotropin stimulation test result cannot exclude benefit of low-dose corticosteroids [7,22]. Although this patient is not 'most severely ill', catecholamine receptor effects may be more important than the immunomodulatory effects of this therapy [22]. This patient remains a candidate for low-dose corticosteroids.

Con's response to Pro's arguments

Katherine G Craig and Keith R Walley

While the foundations of the pro/con debates are remarkably similar, the resulting recommendations are not. Dr Ritacca and colleagues suggest that "appropriate supplementation of corticosteroids [be] part of the regimen of supportive care". There are several problems with this statement. First, with the level of evidence currently available it must be recognized that the use of steroids in sepsis, while promising, is still experimental, and should not be given the same status as routine measures of supportive care. Second, even if a physician makes a conscious decision to try steroids, there are again no data to suggest a dose or timing for 'appropriate supplementation'.

Much work remains to be carried out in this field. We urge restraint and recognition of the potential adverse side effects of, and lack of clear evidence for, steroid therapy in sepsis.

Abbreviations

ACTH: 

ACTH = adrenocorticotrophic hormone.

Authors’ Affiliations

(1)
Resident, Department of Medicine, University of Toronto
(2)
Resident, Division of Thoracic Surgery, University of Toronto
(3)
Resident, Division of Critical Care Medicine, Mount Sinai Hospital
(4)
Lecturer, Department of Medicine, University of Toronto
(5)
Staff Intensivist, Division of Critical Care Medicine, Mount Sinai Hospital
(6)
Fellow in Critical Care Medicine, Division of Critical Care, University of British Columbia
(7)
Professor of Medicine, Division of Critical Care, University of British Columbia

References

  1. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23: 1430-1439. 10.1097/00003246-199508000-00019View ArticlePubMedGoogle Scholar
  2. Lefering R, Neugebauer EAM: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995, 23: 1294-1303. 10.1097/00003246-199507000-00021View ArticlePubMedGoogle Scholar
  3. Annane D, Sébille V, Troché G, Raphaël J, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283: 1038-1045. 10.1001/jama.283.8.1038View ArticlePubMedGoogle Scholar
  4. Barnes PJ, Adcock IM: Glucocorticoid receptors. In The Lung: Scientific Foundations Edited by: West JB, Barnes PJ, Weibel ER, Crystal RG. Philadelphia: Lippincott-Raven Publishers, 1997: 37-55Google Scholar
  5. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332: 1351-1362. 10.1056/NEJM199505183322008View ArticlePubMedGoogle Scholar
  6. Barnes P: Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995, 152: 838-860.View ArticlePubMedGoogle Scholar
  7. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26: 645-650. 10.1097/00003246-199804000-00010View ArticlePubMedGoogle Scholar
  8. Briegel J, Forst H, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single center study. Crit Care Med 1999, 27: 723-732. 10.1097/00003246-199904000-00025View ArticlePubMedGoogle Scholar
  9. Annane D: Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock [abstract]. Crit Care Med 2000, 28: A63.View ArticleGoogle Scholar
  10. Schelling G, Stoll C, Kapfhammer HP, Rothenhausler HB, Krauseneck T, Durst K, Haller M, Briegel J: The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit Care Med 1999, 27: 2678-2683. 10.1097/00003246-199912000-00012View ArticlePubMedGoogle Scholar
  11. Balk RA: Severe sepsis and septic shock: definitions, epidemiology, and clinical manifestations. Crit Care Clin 2000, 16: 179-192.View ArticlePubMedGoogle Scholar
  12. Fisher CJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines D, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994, 271: 1836-1843. 10.1001/jama.271.23.1836View ArticlePubMedGoogle Scholar
  13. Abraham E, Wunderlink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multi-center clinical trial. JAMA 1995, 273: 934-941. 10.1001/jama.273.12.934View ArticlePubMedGoogle Scholar
  14. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, for the HA-1A sepsis study group: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991, 324: 429-436.View ArticlePubMedGoogle Scholar
  15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001View ArticlePubMedGoogle Scholar
  16. Lamberts SWJ, Bruining HA, de Jong FH: Corticosteroid therapy in severe illness. N Engl J Med 1997, 337: 1285-1292. 10.1056/NEJM199710303371807View ArticlePubMedGoogle Scholar
  17. Schroeder S, Wichers M, Klingmüller D, Höfer M, Lehmann LE, von Spiegel T, Hering R, Putensen C, Hoeft A, Stüber F: The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001, 29: 310-316. 10.1097/00003246-200102000-00017View ArticlePubMedGoogle Scholar
  18. Califf RM, O'Connor CM: Beta-blocker therapy for heart failure: the evidence is in, now the work begins. JAMA 2000, 283: 1335-1337. 10.1001/jama.283.10.1335View ArticlePubMedGoogle Scholar
  19. Jurney TH, Cockrell JL, Lindberg JS, Lamiell JM, Wade CE: Spectrum of cortisol and response to ACTH in ICU patients. Chest 1987, 92: 292-295.View ArticlePubMedGoogle Scholar
  20. Drucker D, Shandling M: Variable adrenocortical function in acute medical illness. Crit Care Med 1985, 13: 477-479.View ArticlePubMedGoogle Scholar
  21. Sibbald WJ, Short A, Cohen M, Wilson RF: Variations in adrenocortical responsiveness during severe bacterial infections. Ann Surg 1977, 186: 29-33.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Matot I, Sprung CL: Corticosteroids in septic shock: resurrection of the last rites. Crit Care Med 1998, 26: 627-630. 10.1097/00003246-199804000-00002View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2002